SMMT - NASDAQ
Summit Therapeutics Inc.
$15.07
+1.4%Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
At a Glance
Live Snapshotsmmt
Selling, General and Administrative Expenses
Last Annual Value
556.70M
3-Year CAGR
175%
5-Year CAGR
96%
10-Year CAGR
54%
Summit Therapeutics Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Summit Therapeutics Inc. NASDAQ:SMMT | 556.70M | 170.2% | 88.1% | 50.1% | |
 Atrium Therapeutics, Inc. NASDAQ:RNA | 41.68M | -8.4% | 9.7% | N/A | |
 Ionis Pharmaceuticals, Inc. NASDAQ:IONS | 394.00M | 19.2% | 18.2% | 23.3% | |
 Universal Health Services, Inc. NYSE:UHS | 8.23B | 4.3% | 5.6% | 5.8% | |
 Exact Sciences Corporation NASDAQ:EXAS | 1.94B | 6.2% | 3.1% | 26.2% | |
 Moderna, Inc. NASDAQ:MRNA | 1.02B | -13.1% | 12.4% | 33.3% | |
 Royalty Pharma plc NASDAQ:RPRX | 573.48M | 31.9% | 25.7% | 23.5% | |
 BridgeBio Pharma, Inc. NASDAQ:BBIO | 555.14M | 54.5% | 23.6% | N/A | |
 Revolution Medicines, Inc. NASDAQ:RVMD | 187.13M | 35.3% | 43.8% | N/A |
Summit Therapeutics Inc. Fair Value Envelope
Related Guides
Continue your SMMT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.